Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2026)

Maravai Lifesciences Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 3.28% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 10166.0% year-over-year to 3.28%; the TTM figure through Mar 2026 stood at 82.19% (up 2776.0% YoY), while the FY2025 annual figure was 115.89%, down 2499.0% from the prior year.
• EBITDA Margin was 3.28% for Q1 2026 at Maravai Lifesciences Holdings, up from 117.91% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 74.44% in Q2 2022 to a low of 239.93% in Q3 2024.
• Historically, EBITDA Margin has averaged 35.81% across 5 years, with a median of 19.36% in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 21688 bps in 2024, then surged 14137 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 53.37% in 2022, then slumped by 118 bps to 9.64% in 2023, then sank by 591 bps to 66.66% in 2024, then sank by 77 bps to 117.91% in 2025, then surged by 97 bps to 3.28% in 2026.
• The last three EBITDA Margin figures came in at 3.28% (Q1 2026), 117.91% (Q4 2025), and 98.56% (Q3 2025), per Business Quant data.